Oral News and Research

RSS

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF).

16 Jun 2015

Vitamin D deficiency can leave people less able to fight HIV-1 infection

Vitamin D plays an important part in the human immune response and deficiency can leave individuals less able to fight infections like HIV-1. Now an international team of researchers has found that high-dose vitamin D supplementation can reverse the deficiency and also improve immune response.

16 Jun 2015

Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.

16 Jun 2015

Laurent reports positive topline results from LAU-7b Phase 1b trial in adult CF patients

Laurent Pharmaceuticals Inc. announced today positive topline results from a Phase 1b clinical trial with LAU-7b in adult CF patients. LAU-7b is a novel oral formulation of fenretinide, a synthetic retinoid investigated for its lipid modulating properties and potential to address the aberrant inflammatory response in CF.

15 Jun 2015

Nutrinia's NTRA-9620 granted FDA orphan drug designation for treatment of short bowel syndrome

Nutrinia, developing therapies to treat rare gastrointestinal disorders, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the company's orally-administered drug for treating short bowel syndrome (SBS) in patients of all ages. Nutrinia plans to begin a pivotal clinical trial in this indication.

15 Jun 2015

Novartis announces FDA approval of Promacta for treatment of children with chronic ITP

Novartis announced today that the US Food and Drug Administration has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.

15 Jun 2015

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Ventana Medical Systems, Inc., a member of the Roche Group, today announced approval of the VENTANA ALK (D5F3) CDx Assay by the US Food and Drug Administration as a companion diagnostic to aid in the identification of patients for Pfizer's FDA approved targeted therapy, XALKORI (crizotinib).

15 Jun 2015

Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

Taiho Pharmaceutical Co., Ltd.(Japan) and Servier (France) announced on June 15 that they have entered into an exclusive license agreement on June 12, 2015 for the development and commercialization of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride) in Europe and other countries.

15 Jun 2015

Study examines mental health prognosis of young VTE patients

EuroHeartCare is the official annual meeting of the Council on Cardiovascular Nursing and Allied Professions of the European Society of Cardiology. The 2015 meeting is held 14 to 15 June in Dubrovnik, Croatia, in collaboration with the Croatian Association of Cardiology Nurses.

15 Jun 2015

Hydroxychloroquine drug fails to reduce mild-moderate pain from primary hand osteoarthritis

The results of an interventional trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that use of the disease-modifying anti-rheumatic drug hydroxychloroquine for 24 weeks did not diminish mild-moderate pain from primary hand osteoarthritis (OA).

14 Jun 2015

Henry Schein named recipient of HKC's Corporate Leader Award

Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, announced today that it has been selected as the recipient of the Corporate Leader Award of the Henry Kaufmann Campgrounds.

13 Jun 2015

Cognitive behavioral therapy can help patients with severe dental anxiety

Adults who suffer from severe dental anxiety (DA) are often dissatisfied with their appearance. The dissatisfaction may be associated with poorer oral health, depression and anxiety. A doctoral thesis at Sahlgrenska Academy found that cognitive behavioral therapy (CBT) help patients with severe DA.

12 Jun 2015

Supporting healthcare technology SMEs: an interview with Gary Stapleton, Chairman, Medilink UK

We operate nationwide, giving advice and support to all of our members to allow them to develop and grow their businesses. We do this by giving bespoke support in areas such as innovation - from concept to commercialisation, public relations, international trade – including access to many export markets, market research and guidance on procurement as well as many other areas.

11 Jun 2015

Non-invasive accupoint electrical stimulation to treat Crohn's disease

An oral abstract presented at the International Neuromodulation Society 12th World Congress today unveiled a new collaboration between U.S. and Chinese into non-invasive accupoint electrical stimulation in Crohn's disease.

10 Jun 2015

Children undergoing deep brain stimulation for generalized dystonia experience better outcomes

Children and adolescents who received deep brain stimulation for generalized dystonia maintained significant symptom relief for up to eight years, according to a study presented today at the 12th World Congress of the International Neuromodulation Society.

10 Jun 2015

$Full clinical trial feasible in refractory chronic angina pectoris$

Full clinical trial feasible in refractory chronic angina pectoris

Results of the world's first publicly funded randomized controlled clinical trial of spinal cord stimulation, being presented today at the 12th World Congress of the International Neuromodulation Society, conclude that a fully powered clinical trial is feasible in refractory chronic angina pectoris, a disabling and persistent chronic pain condition.

10 Jun 2015

WHO's updated essential medicines list includes progesterone contraceptive vaginal ring

The World Health Organization released its 2015 updated essential medicines list and for the first time included the progesterone contraceptive vaginal ring (CVR), a contraceptive safe and effective for lactating women in the postpartum period.

10 Jun 2015

Simple steps help accelerate recovery, reduce cost of care in people undergoing colorectal surgery

Simple steps that include the consistent use of experienced medical teams for a single type of surgery, preemptive antibiotics before the procedure, less reliance on potent opioids during recovery and urging patients to get out of bed and move around sooner can not only prevent infections, blood clots and other serious complications in people undergoing colorectal operations, but can also accelerate recovery and reduce cost of care, according to results of an ongoing program at The Johns Hopkins Hospital.

10 Jun 2015

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.

10 Jun 2015

Lycera forms exclusive global collaboration with Celgene

Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the formation of an exclusive global collaboration with Celgene Corporation to take forward Lycera's proprietary pipeline for cancer and immune-mediated diseases.

9 Jun 2015

Oral News and Research

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Vitamin D deficiency can leave people less able to fight HIV-1 infection

Novartis presents positive Phase III results of Farydak therapy at EHA

Laurent reports positive topline results from LAU-7b Phase 1b trial in adult CF patients

Nutrinia's NTRA-9620 granted FDA orphan drug designation for treatment of short bowel syndrome

Novartis announces FDA approval of Promacta for treatment of children with chronic ITP

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

Study examines mental health prognosis of young VTE patients

Hydroxychloroquine drug fails to reduce mild-moderate pain from primary hand osteoarthritis

Henry Schein named recipient of HKC's Corporate Leader Award

Cognitive behavioral therapy can help patients with severe dental anxiety

Supporting healthcare technology SMEs: an interview with Gary Stapleton, Chairman, Medilink UK

Non-invasive accupoint electrical stimulation to treat Crohn's disease

Children undergoing deep brain stimulation for generalized dystonia experience better outcomes

Full clinical trial feasible in refractory chronic angina pectoris

WHO's updated essential medicines list includes progesterone contraceptive vaginal ring

Simple steps help accelerate recovery, reduce cost of care in people undergoing colorectal surgery

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

Lycera forms exclusive global collaboration with Celgene

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News